

Hiroyuki Uchida

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2695655/publications.pdf>

Version: 2024-02-01

321
papers

6,789
citations

66343
42
h-index

110387
64
g-index

341
all docs

341
docs citations

341
times ranked

7271
citing authors

#	ARTICLE	IF	CITATIONS
1	Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of 1H-magnetic resonance spectroscopy studies. <i>Molecular Psychiatry</i> , 2022, 27, 744-757.	7.9	60
2	Increasing trend in the prevalence of alcohol-sensitive individuals with alcohol use disorder over the past 40 years. <i>Psychiatry and Clinical Neurosciences</i> , 2022, 76, 32-33.	1.8	2
3	Influence of alcohol and acetaldehyde on cognitive function: findings from an alcohol clamp study in healthy young adults. <i>Addiction</i> , 2022, 117, 934-945.	3.3	3
4	Investigating structural subdivisions of the anterior cingulate cortex in schizophrenia, with implications for treatment resistance and glutamatergic levels. <i>Journal of Psychiatry and Neuroscience</i> , 2022, 47, E1-E10.	2.4	12
5	MAP Bayesian modelling combining striatal dopamine receptor occupancy and plasma concentrations to optimize antipsychotic dose regimens in individual patients. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 3341-3350.	2.4	2
6	Decision tree classification of cognitive functions with D2 receptor occupancy and illness severity in late-life schizophrenia. <i>Schizophrenia Research</i> , 2022, 241, 113-115.	2.0	1
7	Drug Combinations for Mood Disorders and Physical Comorbidities That Need Attention: A Cross-Sectional National Database Survey. <i>Pharmacopsychiatry</i> , 2022, 55, 157-162.	3.3	1
8	AMPA receptors in schizophrenia: A systematic review of postmortem studies on receptor subunit expression and binding. <i>Schizophrenia Research</i> , 2022, 243, 98-109.	2.0	7
9	Clozapine Once-Daily Versus Divided Dosing Regimen. <i>Journal of Clinical Psychopharmacology</i> , 2022, 42, 163-168.	1.4	7
10	Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment. <i>Molecular Psychiatry</i> , 2022, 27, 2950-2967.	7.9	44
11	High-resolution X-ray study of supernova remnant J0453.6+6829 with unusually high forbidden-to-resonance ratio. <i>Publication of the Astronomical Society of Japan</i> , 2022, 74, 757-766.	2.5	4
12	Patterns of functional connectivity alterations induced by alcohol reflect somatostatin interneuron expression in the human cerebral cortex. <i>Scientific Reports</i> , 2022, 12, 7896.	3.3	8
13	X-ray radiation damage effects on double-SOI pixel detectors for the future astronomical satellite FORCE. <i>Journal of Astronomical Telescopes, Instruments, and Systems</i> , 2022, 8, .	1.8	2
14	Prognostic impact of <i>PDGFRA</i> gain/amplification and <i>MGMT</i> promoter methylation status in patients with <i>IDH</i> wild-type glioblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	3
15	Towards safer risperidone prescribing in Alzheimer's disease. <i>British Journal of Psychiatry</i> , 2021, 218, 268-275.	2.8	9
16	Effects of 30-minute single sessions of yoga and Pilates on frailty in patients with psychiatric disorders: A pilot randomized controlled trial. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 618-620.	2.7	1
17	Low-energy X-ray performance of SOI pixel sensors for astronomy, "XRPIX". <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2021, 986, 164745.	1.6	5
18	Translational medicine of the glutamate AMPA receptor. <i>Proceedings of the Japan Academy Series B: Physical and Biological Sciences</i> , 2021, 97, 1-21.	3.8	6

#	ARTICLE	IF	CITATIONS
19	Comprehensive assessment of exposure to clozapine in association with side effects among patients with treatment-resistant schizophrenia: a population pharmacokinetic study. <i>Therapeutic Advances in Psychopharmacology</i> , 2021, 11, 204512532110161.	2.7	1
20	Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma. <i>Neuro-Oncology</i> , 2021, 23, 945-954.	1.2	11
21	Continuous versus extended antipsychotic dosing in schizophrenia: Less is more. <i>Behavioural Brain Research</i> , 2021, 401, 113076.	2.2	9
22	Prescription patterns in patients with schizophrenia who discontinued long-acting injectable antipsychotics: A chart-review. <i>Psychiatry and Clinical Neurosciences</i> , 2021, 75, 184-185.	1.8	1
23	Development of diagnostic criteria and severity scale for polydipsia: A systematic literature review and well-experienced clinicians' consensus. <i>Psychiatry Research</i> , 2021, 297, 113708.	3.3	1
24	Pre-existing psychiatric disorder is related to lower mortality from road traffic accident: A Japanese nationwide retrospective cohort study. <i>Injury</i> , 2021, 52, 1390-1395.	1.7	0
25	Proton radiation hardness of x-ray SOI pixel sensors with pinned depleted diode structure. <i>Journal of Astronomical Telescopes, Instruments, and Systems</i> , 2021, 7, .	1.8	3
26	Development of a risk stratification scoring system for deep vein thrombosis upon psychiatric admission. <i>Journal of Psychosomatic Research</i> , 2021, 147, 110540.	2.6	2
27	Antipsychotic treatment strategies for acute phase and treatment resistance in schizophrenia: A systematic review of the guidelines and algorithms. <i>Schizophrenia Research</i> , 2021, 236, 142-155.	2.0	18
28	Pharmacological Treatment of Schizophrenia: Japanese Expert Consensus. <i>Pharmacopsychiatry</i> , 2021, 54, 60-67.	3.3	10
29	Dimensional distribution of cortical abnormality across antipsychotics treatment-resistant and responsive schizophrenia. <i>NeuroImage: Clinical</i> , 2021, 32, 102852.	2.7	9
30	Clinical Characteristics of Patients with Schizophrenia Maintained without Antipsychotics: A Cross-sectional Survey of a Case Series. <i>Clinical Psychopharmacology and Neuroscience</i> , 2021, 19, 773-779.	2.0	0
31	Effects of Discontinuation of Drugs Used for Augmentation Therapy on Treatment Outcomes in Depression: A Systematic Review and Meta-analysis. <i>Pharmacopsychiatry</i> , 2021, 54, 106-116.	3.3	1
32	Cancellation of outpatient appointments in patients with attention-deficit/hyperactivity disorder. <i>PLoS ONE</i> , 2021, 16, e0260431.	2.5	2
33	Relationship between polydipsia and antipsychotics: A systematic review of clinical studies and case reports. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 96, 109756.	4.8	14
34	Lower Proportion of Fatal Arrhythmia in Sudden Cardiac Arrest Among Patients With Severe Mental Illness Than Nonpsychiatric Patients. <i>Psychosomatics</i> , 2020, 61, 24-30.	2.5	4
35	Predicting relapse with residual symptoms in schizophrenia: A secondary analysis of the PROACTIVE trial. <i>Schizophrenia Research</i> , 2020, 215, 173-180.	2.0	7
36	Levels of glutamatergic neurometabolites in patients with severe treatment-resistant schizophrenia: a proton magnetic resonance spectroscopy study. <i>Neuropsychopharmacology</i> , 2020, 45, 632-640.	5.4	50

#	ARTICLE	IF	CITATIONS
37	Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials. <i>Neuropsychopharmacology</i> , 2020, 45, 887-901.	5.4	41
38	Antipsychotic treatment in the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms. <i>Schizophrenia Research</i> , 2020, 215, 8-16.	2.0	49
39	T166. VISUALIZATION OF AMPA RECEPTORS IN PATIENTS WITH SCHIZOPHRENIA AND DEPRESSION: THE FIRST PET IMAGING STUDY. <i>Schizophrenia Bulletin</i> , 2020, 46, S294-S295.	4.3	0
40	M23. ALTERATION OF REGIONAL CEREBRAL BLOOD FLOW MEASURED BY ARTERIAL SPIN LABELING IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2020, 46, S142-S142.	4.3	0
41	Radiation damage effects on double-SOI pixel sensors for X-ray astronomy. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2020, 978, 164435.	1.6	6
42	Life-Threatening Serotonin Syndrome Precipitated by Discontinuation of Serotonin-Dopamine Antagonist in the Presence of Serotonergic Agents: A Case Report. <i>Clinical Neuropharmacology</i> , 2020, 43, 81-83.	0.7	3
43	Gap between patients with schizophrenia and their psychiatrists on the needs to psychopharmacological treatment: A cross-sectional study. <i>Neuropsychopharmacology Reports</i> , 2020, 40, 232-238.	2.3	4
44	Prescription patterns of psychotropics in patients receiving synthetic glucocorticoids. <i>Acta Psychiatrica Scandinavica</i> , 2020, 142, 242-248.	4.5	1
45	Diffuse Large B-Cell Lymphoma of the Central Nervous System Manifesting with Intratumoral Hemorrhage: A Case Report and Literature Review. <i>World Neurosurgery</i> , 2020, 143, 490-494.	1.3	3
46	Optical blocking performance of CCDs developed for the X-ray Astronomy Satellite XRISM. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2020, 978, 164374.	1.6	2
47	A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas. <i>Cancer Science</i> , 2020, 111, 3902-3911.	3.9	34
48	Temporal and spatial variation of synchrotron X-ray stripes in Tycho's supernova remnant. <i>Publication of the Astronomical Society of Japan</i> , 2020, 72, .	2.5	7
49	Time Variability of Nonthermal X-Ray Stripes in Tycho's Supernova Remnant with Chandra. <i>Astrophysical Journal</i> , 2020, 894, 50.	4.5	11
50	Pharmacological management of bipolar disorder: Japanese expert consensus. <i>Bipolar Disorders</i> , 2020, 22, 822-830.	1.9	16
51	Reliability of the Glasgow Antipsychotic Side-effects Scale for Clozapine Japanese version (GASS-C-J). <i>PLoS ONE</i> , 2020, 15, e0234864.	2.5	2
52	Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia. <i>Neuropsychopharmacology Reports</i> , 2020, 40, 138-149.	2.3	5
53	Visualization of AMPA Receptors in Patients With Depression, Bipolar Disorder, and Schizophrenia: The First PET Imaging Study. <i>Biological Psychiatry</i> , 2020, 87, S113.	1.3	0
54	Quality of life changes in response to yoga therapy in patients with schizophrenia: Reanalysis of Three randomized controlled trials. <i>Asian Journal of Psychiatry</i> , 2020, 54, 102250.	2.0	1

#	ARTICLE	IF	CITATIONS
55	How common is pulmonary embolism compared to acute myocardial infarction among patients with severe mental illnesses?. <i>Psychiatry and Clinical Neurosciences</i> , 2020, 74, 277-278.	1.8	6
56	White matter microstructural organizations in patients with severe treatment-resistant schizophrenia: A diffusion tensor imaging study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 100, 109871.	4.8	21
57	Visualization of AMPA receptors in living human brain with positron emission tomography. <i>Nature Medicine</i> , 2020, 26, 281-288.	30.7	50
58	Pharmacological management of depression: Japanese expert consensus. <i>Journal of Affective Disorders</i> , 2020, 266, 626-632.	4.1	30
59	<p>Drug Attitude, Insight, and Patientâ€™s Knowledge About Prescribed Antipsychotics in Schizophrenia: A Cross-Sectional Survey<p>. <i>Neuropsychiatric Disease and Treatment</i> , 2020, Volume 16, 781-787.	2.2	15
60	LGG-20. CLINICAL FEATURES AND TREATMENT RESULTS FOR PEDIATRIC OPTICO-HYPOTHALAMIC ASTROCYTOMA. <i>Neuro-Oncology</i> , 2020, 22, iii370-iii370.	1.2	0
61	LGG-32. CLINICAL OUTCOME OF PEDIATRIC GLIOMAS IN SINGLE INSTITUTION. <i>Neuro-Oncology</i> , 2020, 22, iii372-iii372.	1.2	0
62	Frontostriatal Structural Connectivity and Striatal Glutamatergic Levels in Treatment-Resistant Schizophrenia: An Integrative Analysis of DTI and 1H-MRS. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	5
63	Long-term proton pump inhibitor use after <i>Helicobacter pylori</i> eradication may create a gastric environment for <i>N</i>-nitrosamine formation and gastric cancer development. <i>Gut</i> , 2019, 68, 1131.2-1131.	12.1	3
64	Discrepancies Between Nomenclature and Indications of Psychotropics. <i>Pharmacopsychiatry</i> , 2019, 52, 175-179.	3.3	2
65	Kampo, A Japanese Traditional Medicinal System for Psychiatric Conditions: A Narrative Review. <i>Pharmacopsychiatry</i> , 2019, 52, 251-260.	3.3	10
66	Measurement of Charge Cloud Size in X-Ray SOI Pixel Sensors. <i>IEEE Transactions on Nuclear Science</i> , 2019, 66, 1897-1905.	2.0	1
67	Circadian patterns of hallucinatory experiences in patients with schizophrenia: Potentials for chrono-pharmacology. <i>Journal of Psychiatric Research</i> , 2019, 117, 1-6.	3.1	7
68	Improvement of clinical clerkship for medical students by incorporating ideas from junior residents: A feasibility study. <i>Asian Journal of Psychiatry</i> , 2019, 44, 110-111.	2.0	1
69	Etiology of outâ€¢ofâ€¢hospital cardiac arrest in psychiatric patients: Chart review. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 243-247.	1.8	3
70	Alteration in AMPA receptor subunit expression and receptor binding among patients with addictive disorders: A systematic review of human postmortem studies. <i>Neuropsychopharmacology Reports</i> , 2019, 39, 148-155.	2.3	6
71	Ionization age of iron ejecta in the Galactic Typeâ€¢II supernova remnant G306.3â€¢0.9. <i>Publication of the Astronomical Society of Japan</i> , 2019, 71, .	2.5	9
72	Mortality from sepsis among patients with schizophrenia and mood disorders in an intensive care unit: A chart review. <i>Psychiatry Research</i> , 2019, 279, 372-373.	3.3	1

#	ARTICLE	IF	CITATIONS
73	ANGI-06. FUNCTION OF FORMIN-LIKE 1 (FMNL1) IN GLIOBLASTOMA MULTIFORME. <i>Neuro-Oncology</i> , 2019, 21, vi31-vi31.	1.2	0
74	PATH-50. ROUTINE MOLECULAR DIAGNOSIS OF GLIOMA PATIENTS USING A GLIOMA-SPECIFIC NGS PANEL. <i>Neuro-Oncology</i> , 2019, 21, vi154-vi155.	1.2	0
75	COT-14 CLINICAL FEATURES OF PEDIATRIC CENTRAL NERVOUS SYSTEM TUMORS. <i>Neuro-Oncology Advances</i> , 2019, 1, ii43-ii43.	0.7	0
76	MPC-15 FEASIBILITY OF GLIOMA SPECIFIC ONCOPANEL IN THE DIAGNOSIS OF GLIOMA. <i>Neuro-Oncology Advances</i> , 2019, 1, ii24-ii24.	0.7	0
77	P.529 Prescription patterns of psychotropic drugs in patients who were receiving steroidal anti-inflammatory drugs: analysis of Japanese national prescription data. <i>European Neuropsychopharmacology</i> , 2019, 29, S373-S374.	0.7	0
78	Concomitant use of alcohol and benzodiazepine hypnotics in psychiatric outpatients. <i>International Clinical Psychopharmacology</i> , 2019, 34, 291-297.	1.7	2
79	Effectiveness and safety of long-term benzodiazepine use in anxiety disorders. <i>International Clinical Psychopharmacology</i> , 2019, 34, 211-221.	1.7	23
80	Factors Associated With Delirium Following Electroconvulsive Therapy. <i>Journal of ECT</i> , 2019, 35, 279-287.	0.6	25
81	Model-Guided Antipsychotic Dose Reduction in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 329-335.	1.4	14
82	P.362 Antipsychotic treatment for the maintenance phase of schizophrenia: An updated systematic review of the guidelines and algorithms. <i>European Neuropsychopharmacology</i> , 2019, 29, S258-S259.	0.7	2
83	The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotic trials of intervention effectiveness (CATIE) data. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 89, 207-213.	4.8	5
84	Placebo effects in adult and adolescent patients with schizophrenia: combined analysis of nine RCT s. <i>Acta Psychiatrica Scandinavica</i> , 2019, 139, 108-116.	4.5	7
85	Impact of subjective vs. objective remission status on subjective cognitive impairments in depression. <i>Journal of Affective Disorders</i> , 2019, 246, 99-104.	4.1	10
86	Evaluation of Kyoto's event-driven X-ray astronomical SOI pixel sensor with a large imaging area. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2019, 924, 400-403.	1.6	4
87	Comparison of emotional processing assessed with fear conditioning by interpersonal conflicts in patients with depression and schizophrenia. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 116-125.	1.8	13
88	Performance of the Silicon-On-Insulator pixel sensor for X-ray astronomy, XRPIX6E, equipped with pinned depleted diode structure. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2019, 924, 468-472.	1.6	12
89	Neuroscience-based Nomenclature: What is it, why is it needed, and what comes next?. <i>Psychiatry and Clinical Neurosciences</i> , 2018, 72, 50-51.	1.8	10
90	Kynurenine pathway in depression: A systematic review and meta-analysis. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 90, 16-25.	6.1	199

#	ARTICLE	IF	CITATIONS
91	A Possible Role of Takotsubo Cardiomyopathy in Ventricular Fibrillation During Delirium Tremens: A Case Report and Literature Review. <i>Psychosomatics</i> , 2018, 59, 293-297.	2.5	8
92	Religiosity and psychological resilience in patients with schizophrenia and bipolar disorder: an international cross-sectional study. <i>Acta Psychiatrica Scandinavica</i> , 2018, 137, 316-327.	4.5	27
93	Prediction Model of Serum Lithium Concentrations. <i>Pharmacopsychiatry</i> , 2018, 51, 82-88.	3.3	8
94	Suzaku X-ray observations of the mixed-morphology supernova remnant CTB 1. Publication of the Astronomical Society of Japan, 2018, 70, .	2.5	13
95	Mood stabilizers as an Achilles' heel for indication-based nomenclature and roles of Neuroscience-based Nomenclature. <i>Psychiatry and Clinical Neurosciences</i> , 2018, 72, 854-855.	1.8	0
96	Detection of polarized gamma-ray emission from the Crab nebula with the Hitomi Soft Gamma-ray Detector. Publication of the Astronomical Society of Japan, 2018, 70, .	2.5	21
97	Recycling and Energy Recovery by Municipal Solid Waste Carbonization Fuel System. <i>Nihon Enerugi Gakkaishi/Journal of the Japan Institute of Energy</i> , 2018, 97, 252-260.	0.2	0
98	Psychopharmacology in Japan. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 415-419.	1.4	4
99	Dietary Nitrite Attenuates Elastase-Induced Pulmonary Emphysema in a Mouse Model. <i>Biological and Pharmaceutical Bulletin</i> , 2018, 41, 1818-1823.	1.4	6
100	Search for thermal X-ray features from the Crab nebula with the Hitomi soft X-ray spectrometer. Publication of the Astronomical Society of Japan, 2018, 70, .	2.5	8
101	Glimpse of the highly obscured HMXB IGR J16318+4848 with Hitomi. Publication of the Astronomical Society of Japan, 2018, 70, .	2.5	4
102	T108. AMPA Receptor Subunit Expression and Receptor Binding in Patients With Major Depressive Disorder: A Systematic Review of Postmortem Studies. <i>Biological Psychiatry</i> , 2018, 83, S170.	1.3	1
103	Hitomi X-ray studies of giant radio pulses from the Crab pulsar. Publication of the Astronomical Society of Japan, 2018, 70, .	2.5	8
104	Clinical Characteristics of Patients With Schizophrenia Who Successfully Discontinued Antipsychotics. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 582-589.	1.4	14
105	Quality of life in stabilized outpatients with bipolar I disorder: Associations with resilience, internalized stigma, and residual symptoms. <i>Journal of Affective Disorders</i> , 2018, 238, 399-404.	4.1	31
106	Measurements of resonant scattering in the Perseus Cluster core with Hitomi SXS. Publication of the Astronomical Society of Japan, 2018, 70, .	2.5	29
107	Hitomi observation of radio galaxy NGC 1275: The first X-ray microcalorimeter spectroscopy of Fe-K \pm line emission from an active galactic nucleus. Publication of the Astronomical Society of Japan, 2018, 70, .	2.5	27
108	Temperature structure in the Perseus cluster core observed with Hitomi. Publication of the Astronomical Society of Japan, 2018, 70, .	2.5	20

#	ARTICLE	IF	CITATIONS
109	Low sense of coherence is associated with anxiety among adults: Results based on data from all 47 prefectures of Japan. <i>Comprehensive Psychiatry</i> , 2018, 86, 131-136.	3.1	9
110	Soft X-ray Imager aboard Hitomi (ASTRO-H). <i>Journal of Astronomical Telescopes, Instruments, and Systems</i> , 2018, 4, 1.	1.8	18
111	Early Placebo Improvement Is a Marker for Subsequent Placebo Response in Long-Acting Injectable Antipsychotic Trials for Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2018, 80, .	2.2	4
112	Lack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 708-716.	1.2	10
113	Insight into illness and its relationship to illness severity, cognition and estimated antipsychotic dopamine receptor occupancy in schizophrenia: An antipsychotic dose reduction study. <i>Psychiatry Research</i> , 2017, 251, 20-25.	3.3	10
114	Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis. <i>Molecular and Clinical Oncology</i> , 2017, 6, 105-110.	1.0	15
115	Inducible and neuronal nitric oxide synthases exert contrasting effects during rat intestinal recovery following fasting. <i>Experimental Biology and Medicine</i> , 2017, 242, 762-772.	2.4	4
116	Vestibular stimulation improves insight into illness in schizophrenia spectrum disorders. <i>Psychiatry Research</i> , 2017, 251, 333-341.	3.3	6
117	Frontal and temporal cortical functional recovery after electroconvulsive therapy for depression: A longitudinal functional near-infrared spectroscopy study. <i>Journal of Psychiatric Research</i> , 2017, 91, 26-35.	3.1	52
118	Representativeness of clinical PET study participants with schizophrenia: A systematic review. <i>Journal of Psychiatric Research</i> , 2017, 88, 72-79.	3.1	6
119	Naming for Psychotropic Drugs: Dilemma and Challenge. <i>Pharmacopsychiatry</i> , 2017, 50, 1-2.	3.3	17
120	The Long-Term Effects of Antipsychotic Medication on Clinical Course in Schizophrenia. <i>American Journal of Psychiatry</i> , 2017, 174, 840-849.	7.2	155
121	Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data. <i>Psychopharmacology</i> , 2017, 234, 2453-2461.	3.1	52
122	Dietary nitrite supplementation attenuates cardiac remodeling in l-NAME-induced hypertensive rats. <i>Nitric Oxide - Biology and Chemistry</i> , 2017, 67, 1-9.	2.7	35
123	Resilience and spirituality in patients with depression and their family members: A cross-sectional study. <i>Comprehensive Psychiatry</i> , 2017, 77, 53-59.	3.1	34
124	Dietary nitrite reverses features of postmenopausal metabolic syndrome induced by high-fat diet and ovariectomy in mice. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2017, 312, E300-E308.	3.5	22
125	Radiologic and histologic features of the T2 hyperintensity rim of meningiomas on magnetic resonance images. <i>Neuroradiology Journal</i> , 2017, 30, 48-56.	1.2	7
126	Immediate vs Gradual Discontinuation in Antipsychotic Switching: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2017, 43, sbw171.	4.3	21

#	ARTICLE	IF	CITATIONS
127	Psychotic Symptoms Associated With Varenicline in a Patient With Alcohol and Nicotine Dependence. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 627-628.	1.4	2
128	Quality of life in schizophrenia and bipolar disorder: The impact of symptomatic remission and resilience. <i>European Psychiatry</i> , 2017, 46, 42-47.	0.2	47
129	Effects of chair yoga therapy on physical fitness in patients with psychiatric disorders: A 12-week single-blind randomized controlled trial. <i>Journal of Psychiatric Research</i> , 2017, 94, 194-201.	3.1	22
130	No Association of Caffeinated Beverage or Caffeine Intake with Prevalence of Urinary Incontinence Among Middle-Aged Japanese Women: A Multicenter Cross-Sectional Study. <i>Journal of Women's Health</i> , 2017, 26, 860-869.	3.3	1
131	194. Exploring Neural Basis of Emotional Cognition Using Fear Conditioning by Interpersonal Conflicts in Patients with Schizophrenia. <i>Biological Psychiatry</i> , 2017, 81, S80-S81.	1.3	0
132	Psychological dependence on antidepressants in patients with panic disorder. <i>International Clinical Psychopharmacology</i> , 2017, 32, 36-40.	1.7	2
133	Patients' Knowledge about Prescribed Antipsychotics and Medication Adherence in Schizophrenia: A Cross-Sectional Survey. <i>Pharmacopsychiatry</i> , 2017, 50, 264-269.	3.3	7
134	Cognition and Dopamine D2 Receptor Availability in the Striatum in Older Patients with Schizophrenia. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 1-10.	1.2	18
135	AMPA receptor subunit expression and receptor binding in patients with addiction: a systematic review of postmortem studies. <i>European Neuropsychopharmacology</i> , 2017, 27, S756-S757.	0.7	0
136	Risk factors of delirium following electroconvulsive therapy: a systematic review. <i>European Neuropsychopharmacology</i> , 2017, 27, S857.	0.7	0
137	Localized recombining plasma in G166.0+4.3: A supernova remnant with an unusual morphology. <i>Publication of the Astronomical Society of Japan</i> , 2017, 69, .	2.5	20
138	Self-rated cognitive functions following chemotherapy in patients with breast cancer: a 6-month prospective study. <i>Neuropsychiatric Disease and Treatment</i> , 2017, Volume 13, 2489-2496.	2.2	8
139	Protective effects of oral glutathione on fasting-induced intestinal atrophy through oxidative stress. <i>World Journal of Gastroenterology</i> , 2017, 23, 6650-6664.	3.3	10
140	Early Improvement of Specific Symptoms Predicts Subsequent Recovery in Bipolar Depression. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e146-e151.	2.2	8
141	A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e844-e851.	2.2	13
142	Placebo Effects in the Treatment of Noncognitive Symptoms of Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2017, 78, e1204-e1210.	2.2	8
143	Early Improvements in Individual Symptoms to Predict Later Remission in Major Depressive Disorder Treated With Mirtazapine. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1111-1119.	2.0	11
144	Reduction of cross-talks between circuit and sensor layer in the Kyoto's X-ray astronomy SOI pixel sensors with Double-SOI wafer. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2016, 831, 61-64.	1.6	12

#	ARTICLE	IF	CITATIONS
145	Incidence of deep vein thrombosis in catatonic patients: A chart review. <i>Psychiatry Research</i> , 2016, 241, 61-65.	3.3	29
146	Clinical and biological correlates of resilience in patients with schizophrenia and bipolar disorder: A cross-sectional study. <i>Schizophrenia Research</i> , 2016, 175, 148-153.	2.0	50
147	Plasma levels and estimated dopamine D2 receptor occupancy of long-acting injectable risperidone during maintenance treatment of schizophrenia: a 3-year follow-up study. <i>Psychopharmacology</i> , 2016, 233, 4003-4010.	3.1	7
148	Quality of life in stabilized patients with schizophrenia is mainly associated with resilience and self-esteem. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 360-367.	4.5	56
149	Development of a Transnasal Delivery System for Recombinant Human Growth Hormone (rhGH): Effects of the Concentration and Molecular Weight of Poly-L-arginine on the Nasal Absorption of rhGH in Rats. <i>Biological and Pharmaceutical Bulletin</i> , 2016, 39, 329-335.	1.4	3
150	Prescription patterns for depression among consultation-liaison psychiatrists and non-psychiatrists: a chart review. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 1084-1085.	2.7	0
151	Relapse of ileus in patients with psychiatric disorders: A 2-year chart review. <i>General Hospital Psychiatry</i> , 2016, 38, 31-36.	2.4	1
152	Postural sway and flexibility in patients with schizophrenia-spectrum disorders: A cross-sectional study. <i>Asian Journal of Psychiatry</i> , 2016, 19, 14-18.	2.0	6
153	Resilience in schizophrenia: A comparative study between a remote island and an urban area in Japan. <i>Schizophrenia Research</i> , 2016, 171, 92-96.	2.0	9
154	Resilience, internalized stigma, self-esteem, and hopelessness among people with schizophrenia: Cultural comparison in Austria and Japan. <i>Schizophrenia Research</i> , 2016, 171, 86-91.	2.0	63
155	Increasing Versus Maintaining the Dose of Olanzapine or Risperidone in Schizophrenia Patients Who Did Not Respond to a Modest Dosage. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 1381-1390.	2.2	11
156	Threshold of Dopamine D _{2/3} Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1557-e1563.	2.2	11
157	Neuroscience-based Nomenclature (NbN) for Clinical Psychopharmacology and Neuroscience. <i>Clinical Psychopharmacology and Neuroscience</i> , 2016, 14, 115-116.	2.0	7
158	Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic Study. <i>Pharmacopsychiatry</i> , 2015, 48, 286-291.	3.3	4
159	Cardiac Sudden Death in Psychiatric Patients. <i>Canadian Journal of Psychiatry</i> , 2015, 60, 203-205.	1.9	7
160	Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review. <i>Canadian Journal of Psychiatry</i> , 2015, 60, 215-222.	1.9	63
161	Language Barriers and Access to Psychiatric Care: A Systematic Review. <i>Psychiatric Services</i> , 2015, 66, 798-805.	2.0	68
162	Discrepancy in Psychological Attitudes Toward Living Donor Liver Transplantation Between Recipients and Donors. <i>Transplantation</i> , 2015, 99, 2551-2555.	1.0	3

#	ARTICLE	IF	CITATIONS
163	NO-Rich Diet for Lifestyle-Related Diseases. <i>Nutrients</i> , 2015, 7, 4911-4937.	4.1	62
164	Fear Conditioning Induced by Interpersonal Conflicts in Healthy Individuals. <i>PLoS ONE</i> , 2015, 10, e0125729.	2.5	5
165	Improvement of spectroscopic performance using a charge-sensitive amplifier circuit for an X-ray astronomical SOI pixel detector. <i>Journal of Instrumentation</i> , 2015, 10, C06005-C06005.	1.2	28
166	Optimization of psychopharmacotherapy for schizophrenia in a male, locked, non-acute unit serving for persistently ill patients over one year. <i>Psychiatry Research</i> , 2015, 228, 26-30.	3.3	1
167	Dopamine D2/3 receptor availability in the striatum of antipsychotic-free older patients with schizophreniaâ€”A [11C]-raclopride PET study. <i>Schizophrenia Research</i> , 2015, 164, 263-267.	2.0	17
168	Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials. <i>Molecular Psychiatry</i> , 2015, 20, 1151-1160.	7.9	78
169	A questionnaire survey of Japanese non-psychiatristsâ€™ attitudes on management of depression in a general hospital. <i>Asian Journal of Psychiatry</i> , 2015, 15, 73-74.	2.0	1
170	Relationships between global assessment of functioning and other rating scales in clinical trials for schizophrenia. <i>Psychiatry Research</i> , 2015, 227, 265-269.	3.3	40
171	Antidepressant dose and treatment response in bipolar depression: Reanalysis of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) data. <i>Journal of Psychiatric Research</i> , 2015, 68, 151-156.	3.1	14
172	Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia. <i>JAMA Psychiatry</i> , 2015, 72, 927.	11.0	77
173	Challenging the need for sustained blockade of dopamine D2 receptor estimated from antipsychotic plasma levels in the maintenance treatment of schizophrenia: A single-blind, randomized, controlled study. <i>Schizophrenia Research</i> , 2015, 164, 149-154.	2.0	12
174	Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial. <i>Schizophrenia Bulletin</i> , 2015, 42, sbv106.	4.3	16
175	A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. <i>European Neuropsychopharmacology</i> , 2015, 25, 2318-2325.	0.7	135
176	Dietary nitrite supplementation improves insulin resistance in type 2 diabetic KK ^{AY} mice. <i>Nitric Oxide - Biology and Chemistry</i> , 2015, 44, 31-38.	2.7	53
177	Dependence on benzodiazepines in patients with panic disorder: A cross-sectional study. <i>Psychiatry and Clinical Neurosciences</i> , 2015, 69, 93-99.	1.8	8
178	Whether to Increase or Maintain Dosage of Mirtazapine in Early Nonimprovers With Depression. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 434-439.	2.2	3
179	Effects of Weekly One-Hour Hatha Yoga Therapy on Resilience and Stress Levels in Patients with Schizophrenia-Spectrum Disorders: An Eight-Week Randomized Controlled Trial. <i>Journal of Alternative and Complementary Medicine</i> , 2014, 20, 823-830.	2.1	61
180	Timing of Adjunctive Therapy in the Treatment of Depression: A Chart Review. <i>Pharmacopsychiatry</i> , 2014, 47, 259-262.	3.3	0

#	ARTICLE	IF	CITATIONS
181	Prophylactic use of heparin for deep vein thrombosis in restrained psychiatric patients: a chart review. <i>General Hospital Psychiatry</i> , 2014, 36, 690-693.	2.4	8
182	A review on schizophrenia and relapse—a quest for user-friendly psychopharmacotherapy. <i>Human Psychopharmacology</i> , 2014, 29, 414-426.	1.5	29
183	Japanese versions of the Executive Interview (J-EXIT25) and the Executive Clock Drawing Task (J-CLOX) for older people. <i>International Psychogeriatrics</i> , 2014, 26, 1387-1397.	1.0	19
184	Lack of Effect of Risperidone or Olanzapine Dose Reduction on Metabolic Parameters, Prolactin, and Corrected QT Interval in Stable Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 517-520.	1.4	6
185	Baseline Difference Between Patients' and Clinicians' Rated Illness Severity Scores and Subsequent Outcomes in Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 297-302.	1.4	10
186	Dose and Dosing Frequency of Long-Acting Injectable Antipsychotics. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 728-735.	1.4	29
187	Effectiveness of Saikokaryukotsuboreito (Herbal Medicine) for Antipsychotic-Induced Sexual Dysfunction in Male Patients with Schizophrenia: A Description of Two Cases. <i>Case Reports in Psychiatry</i> , 2014, 2014, 1-3.	0.5	6
188	Incidence of Deep Vein Thrombosis in Restrained Psychiatric Patients. <i>Psychosomatics</i> , 2014, 55, 69-75.	2.5	35
189	Successful withdrawal from antipsychotic treatment in elderly male inpatients with schizophrenia—Description of four cases and review of the literature. <i>Psychiatry Research</i> , 2014, 220, 152-157.	3.3	8
190	Pharmacological Strategies to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin</i> , 2014, 40, 1385-1403.	4.3	166
191	Tardive dyskinesia in relation to estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data. <i>Schizophrenia Research</i> , 2014, 153, 184-188.	2.0	27
192	Therapeutic Window for Striatal Dopamine D2/3 Receptor Occupancy in Older Patients with Schizophrenia: A Pilot PET Study. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 1007-1016.	1.2	24
193	Lack of effect of risperidone or olanzapine dose reduction on subjective experiences in stable patients with schizophrenia. <i>Psychiatry Research</i> , 2014, 218, 244-246.	3.3	2
194	Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 1083-1093.	2.1	131
195	Impact of Once- Versus Twice-Daily Perphenazine Dosing on Clinical Outcomes. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 506-511.	2.2	16
196	Dose Reduction of Risperidone and Olanzapine and Estimated Dopamine D ₂ Receptor Occupancy in Stable Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 1209-1214.	2.2	14
197	Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data. <i>Schizophrenia Bulletin</i> , 2013, 39, 564-574.	4.3	109
198	Dopamine D2/3 occupancy of ziprasidone across a day: a within-subject PET study. <i>Psychopharmacology</i> , 2013, 228, 43-51.	3.1	15

#	ARTICLE	IF	CITATIONS
199	The impact of prolactin-raising antipsychotics on bone mineral density in patients with schizophrenia: Findings from a longitudinal observational cohort. <i>Schizophrenia Research</i> , 2013, 147, 383-386.	2.0	26
200	Trajectories of individual symptoms in remitters versus non-remitters with depression. <i>Journal of Affective Disorders</i> , 2013, 151, 506-513.	4.1	41
201	Melancholic and reactive depression: a reappraisal of old categories. <i>BMC Psychiatry</i> , 2013, 13, 311.	2.6	16
202	Antipsychotic polypharmacy: A Japanese survey of prescribers' attitudes and rationales. <i>Psychiatry Research</i> , 2013, 209, 406-411.	3.3	28
203	Interventions to reduce antipsychotic polypharmacy: A systematic review. <i>Schizophrenia Research</i> , 2013, 143, 215-220.	2.0	46
204	Estimated dopamine D2 receptor occupancy from plasma concentrations of atypical antipsychotics and subjective experience/drug attitude in schizophrenia: An analysis of the CATIE data. <i>Schizophrenia Research</i> , 2013, 150, 373-379.	2.0	8
205	Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013, 45, 178-182.	4.8	25
206	Oversight of constipation in inpatients with schizophrenia: a cross-sectional study. <i>General Hospital Psychiatry</i> , 2013, 35, 649-652.	2.4	21
207	Effects of yoga therapy on postural stability in patients with schizophrenia-spectrum disorders: A single-blind randomized controlled trial. <i>Journal of Psychiatric Research</i> , 2013, 47, 1744-1750.	3.1	48
208	Association between antidepressant side effects and functional impairment in patients with major depressive disorders. <i>Psychiatry Research</i> , 2013, 210, 127-133.	3.3	16
209	Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics. <i>International Clinical Psychopharmacology</i> , 2013, 28, 261-266.	1.7	7
210	Absence of evidence that the pro re nata regimen confers benefit. <i>International Clinical Psychopharmacology</i> , 2013, 28, 228-237.	1.7	11
211	Estimated Dopamine D2 Receptor Occupancy and Remission in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2013, 33, 682-685.	1.4	23
212	Reintroduction of Clozapine After Perforation of the Large Intestine—A Case Report and Review of the Literature. <i>Annals of Pharmacotherapy</i> , 2013, 47, e31-e31.	1.9	17
213	Effects of Risperidone and Olanzapine Dose Reduction on Cognitive Function in Stable Patients With Schizophrenia: An Open-Label, Randomized, Controlled, Pilot Study. <i>Schizophrenia Bulletin</i> , 2013, 39, 993-998.	4.3	92
214	Poly-L-arginine-Induced Internalization of Tight Junction Proteins Increases the Paracellular Permeability of the Caco-2 Cell Monolayer to Hydrophilic Macromolecules. <i>Biological and Pharmaceutical Bulletin</i> , 2013, 36, 432-441.	1.4	11
215	E-030—Multi-staged Embolisation of Neonatal Vein of Galen Aneurysmal Malformation through a 3-French Sheath. <i>Journal of NeuroInterventional Surgery</i> , 2013, 5, A47.1-A47.	3.3	0
216	Discovery of a recombination dominant plasma: a relic of a giant flare of Sgr A*. <i>Proceedings of the International Astronomical Union</i> , 2013, 9, 349-353.	0.0	0

#	ARTICLE	IF	CITATIONS
217	An open-label study of algorithm-based treatment versus treatment-as-usual for patients with schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 1553.	2.2	2
218	Antipsychotic Polypharmacy in Schizophrenia. How to Counteract This Common Practice?. , 2013, , 81-107.		0
219	Factor Structure of the Targeted Inventory on Problems in Schizophrenia. <i>Clinical Psychopharmacology and Neuroscience</i> , 2013, 11, 18-23.	2.0	0
220	How Psychotropic Polypharmacy in Schizophrenia Begins: A Longitudinal Perspective. <i>Pharmacopsychiatry</i> , 2012, 45, 133-137.	3.3	13
221	Predicting Plasma Concentration of Risperidone Associated With Dosage Change. <i>Therapeutic Drug Monitoring</i> , 2012, 34, 182-187.	2.0	23
222	Age and Sex Impact Clozapine Plasma Concentrations in Inpatients and Outpatients With Schizophrenia. <i>American Journal of Geriatric Psychiatry</i> , 2012, 20, 53-60.	1.2	44
223	Deficit status in bipolar disorder: Investigation on prevalence rate and description of seven cases. <i>Journal of Affective Disorders</i> , 2012, 143, 248-252.	4.1	3
224	Defining treatment-resistant schizophrenia and response to antipsychotics: A review and recommendation. <i>Psychiatry Research</i> , 2012, 197, 1-6.	3.3	148
225	Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: A cross-sectional study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2012, 37, 182-187.	4.8	21
226	Dental conditions in inpatients with schizophrenia: A large-scale multi-site survey. <i>BMC Oral Health</i> , 2012, 12, 32.	2.3	38
227	Antipsychotic treatment for schizophrenia in the maintenance phase: A systematic review of the guidelines and algorithms. <i>Schizophrenia Research</i> , 2012, 134, 219-225.	2.0	100
228	The 3rd Schizophrenia International Research Society Conference, 14â€“18 April 2012, Florence, Italy: Summaries of oral sessions. <i>Schizophrenia Research</i> , 2012, 141, e1-e24.	2.0	8
229	Effects of zonisamide on tardive dyskinesia: A preliminary open-label trial. <i>Journal of the Neurological Sciences</i> , 2012, 315, 137-140.	0.6	19
230	Coping strategies for antidepressant side effects: An Internet survey. <i>Journal of Affective Disorders</i> , 2012, 143, 89-94.	4.1	13
231	Therapeutic Window for Striatal Dopamine D2/3 Receptor Occupancy in Older Patients With Schizophrenia. <i>American Journal of Geriatric Psychiatry</i> , 2012, , 1.	1.2	12
232	How Successful Are Physicians in Eliciting the Truth From Their Patients?. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 311-317.	2.2	17
233	A Cross-Sectional Study of Plasma Risperidone Levels With Risperidone Long-Acting Injectable. <i>Journal of Clinical Psychiatry</i> , 2012, 73, 1147-1152.	2.2	17
234	The evolution of antipsychotic switch and polypharmacy in natural practice â€“ A longitudinal perspective. <i>Schizophrenia Research</i> , 2011, 130, 40-46.	2.0	57

#	ARTICLE	IF	CITATIONS
235	Management of Schizophrenia in Late Life with Antipsychotic Medications. <i>Drugs and Aging</i> , 2011, 28, 961-980.	2.7	26
236	Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: A randomized open-label trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 1983-1989.	4.8	38
237	Treatment resistant schizophrenia and response to antipsychotics: A review. <i>Schizophrenia Research</i> , 2011, 133, 54-62.	2.0	99
238	P.2.a.008 Why do patients not tell the truth to their physician? A large-scale internet survey. <i>European Neuropsychopharmacology</i> , 2011, 21, S358-S359.	0.7	0
239	P.3.c.063 The evolution of antipsychotic switch and polypharmacy in natural practice: a longitudinal perspective. <i>European Neuropsychopharmacology</i> , 2011, 21, S505.	0.7	0
240	Balancing Potential Risks and Benefits of Adjunctive Use of Aripiprazole With Risperidone for the Treatment of Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 136-137.	1.4	0
241	Dopamine D2 Receptor Occupancy and Clinical Effects. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 497-502.	1.4	117
242	Clinical and Demographic Characteristics Associated With Postural Instability in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 16-21.	1.4	15
243	Predicting Dopamine D2 Receptor Occupancy From Plasma Levels of Antipsychotic Drugs. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 318-325.	1.4	77
244	Time course of improvement with antipsychotic medication in treatment-resistant schizophrenia. <i>British Journal of Psychiatry</i> , 2011, 199, 275-280.	2.8	40
245	Pisa syndrome caused by an acetylcholinesterase inhibitor in a patient with dementia with Lewy bodies. <i>Psychiatry and Clinical Neurosciences</i> , 2011, 65, 299-299.	1.8	20
246	Plasma substance P level in patients with schizophrenia: A cross-sectional study. <i>Psychiatry and Clinical Neurosciences</i> , 2011, 65, 526-528.	1.8	6
247	Impact of feedback from pharmacists in reducing antipsychotic polypharmacy in schizophrenia. <i>Psychiatry and Clinical Neurosciences</i> , 2011, 65, 676-678.	1.8	22
248	How long to wait before reducing antipsychotic dosage in stabilized patients with schizophrenia? A retrospective chart review. <i>Journal of Psychiatric Research</i> , 2011, 45, 1083-1088.	3.1	6
249	Subjective recognition of adverse events with antidepressant in people with depression: A prospective study. <i>Journal of Affective Disorders</i> , 2011, 135, 347-353.	4.1	7
250	Patients' attitudes toward side effects of antidepressants: an Internet survey. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 103-109.	3.2	23
251	Patients' trust in their psychiatrist: a cross-sectional survey. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2011, 261, 603-608.	3.2	10
252	A Tipping Point in Drug Dosing in Late-Life Schizophrenia. <i>Current Psychiatry Reports</i> , 2011, 13, 225-233.	4.5	5

#	ARTICLE	IF	CITATIONS
253	Effects of aging on 5-HT _{2A} binding: a HRRT PET study with and without partial volume corrections. International Journal of Geriatric Psychiatry, 2011, 26, 1300-1308.	2.7	26
254	Influence of Anticholinergic Activity in Serum on Clinical Symptoms of Alzheimer's Disease. Neuropsychobiology, 2011, 63, 147-153.	1.9	32
255	Low Dose vs Standard Dose of Antipsychotics for Relapse Prevention in Schizophrenia: Meta-analysis. Schizophrenia Bulletin, 2011, 37, 788-799.	4.3	94
256	Factors associated with response to clozapine in schizophrenia: a review. Psychopharmacology Bulletin, 2011, 44, 32-60.	0.0	31
257	Clozapine and Global Cognition in Schizophrenia. Journal of Clinical Psychopharmacology, 2010, 30, 431-436.	1.4	35
258	Magnitude of Rater Differences in Assessment Scales for Schizophrenia. Journal of Clinical Psychopharmacology, 2010, 30, 607-611.	1.4	9
259	Are Antipsychotic Prescribing Patterns Different in Older and Younger Adults?: A Survey of 1357 Psychiatric Inpatients in Toronto. Canadian Journal of Psychiatry, 2010, 55, 248-254.	1.9	10
260	Depression Severity and Effect of Antidepressant Medications. JAMA - Journal of the American Medical Association, 2010, 303, 1596.	7.4	2
261	Sensitivity to Antipsychotic Drugs in Older Adults. Current Psychiatry Reports, 2010, 12, 28-33.	4.5	35
262	Effects of discontinuing benzodiazepine-derivative hypnotics on postural sway and cognitive functions in the elderly. International Journal of Geriatric Psychiatry, 2010, 25, 1259-1265.	2.7	31
263	Adverse effects of anticholinergic activity on cognitive functions in Alzheimer's disease. Psychogeriatrics, 2010, 10, 34-38.	1.2	31
264	Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: One-year follow-up study. Psychiatry and Clinical Neurosciences, 2010, 64, 104-106.	1.8	22
265	Analysis of Antipsychotic Dose Reduction. American Journal of Psychiatry, 2010, 167, 994-994.	7.2	2
266	LOW DOSE VS. STANDARD DOSE OF ANTIPSYCHOTICS FOR RELAPSE PREVENTION IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS. Schizophrenia Research, 2010, 117, 503-504.	2.0	0
267	Accelerating response to antidepressant treatment in depression: A review and clinical suggestions. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 259-264.	4.8	59
268	Potential risks of adjunctive use of atypical antipsychotic drugs for the treatment of depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 435-436.	4.8	0
269	Potentials and current limitations of brain stimulation therapies to accelerate antidepressant response. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 439-440.	4.8	0
270	Oral nitrite ameliorates dextran sulfate sodium-induced acute experimental colitis in mice. Nitric Oxide - Biology and Chemistry, 2010, 23, 65-73.	2.7	36

#	ARTICLE	IF	CITATIONS
271	Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. <i>Human Psychopharmacology</i> , 2009, 24, 628-638.	1.5	51
272	Test-retest variability of high resolution positron emission tomography (PET) imaging of cortical serotonin (5HT _{2A}) receptors in older, healthy adults. <i>BMC Medical Imaging</i> , 2009, 9, 12.	2.7	10
273	Persistence and compliance to antidepressant treatment in patients with depression: A chart review. <i>BMC Psychiatry</i> , 2009, 9, 38.	2.6	147
274	Predicting Age-Specific Dosing of Antipsychotics. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 360-362.	4.7	45
275	Should adjunctive antipsychotic treatment be continued in remitted patients with depression?. <i>Psychiatry and Clinical Neurosciences</i> , 2009, 63, 126-126.	1.8	2
276	Survey of benzodiazepine and antidepressant use in outpatients with mood disorders in Japan. <i>Psychiatry and Clinical Neurosciences</i> , 2009, 63, 244-246.	1.8	20
277	Strict use of terminology: Reply to Dr Toda. <i>Psychiatry and Clinical Neurosciences</i> , 2009, 63, 430-431.	1.8	1
278	Antipsychotic-induced paroxysmal perceptual alteration in a patient with bipolar disorder. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 160-161.	4.8	7
279	Dosing of antipsychotics in schizophrenia across the life-spectrum. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2009, 33, 917-920.	4.8	28
280	Benzodiazepine and antidepressant use in elderly patients with anxiety disorders: A survey of 796 outpatients in Japan. <i>Journal of Anxiety Disorders</i> , 2009, 23, 477-481.	3.2	37
281	Long-term stability of measuring D ₂ receptors in schizophrenia patients treated with antipsychotics. <i>Schizophrenia Research</i> , 2009, 109, 130-133.	2.0	15
282	P.2.a.018 Persistence and compliance to antidepressant treatment in patients with depression: a chart review. <i>European Neuropsychopharmacology</i> , 2009, 19, S370-S371.	0.7	0
283	P.3.c.030 Low dose versus standard dose of antipsychotics for relapse prevention in schizophrenia: a meta-analysis. <i>European Neuropsychopharmacology</i> , 2009, 19, S527-S528.	0.7	0
284	Sensitivity of Older Patients to Antipsychotic Motor Side Effects: A PET Study Examining Potential Mechanisms. <i>American Journal of Geriatric Psychiatry</i> , 2009, 17, 255-263.	1.2	58
285	Clozapine Exposure and the Impact of Smoking and Gender: A Population Pharmacokinetic Study. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 360-366.	2.0	57
286	Impacts of Switching Antidepressants After Successful Electroconvulsive Therapy on the Maintenance of Clinical Remission in Patients With Treatment-Resistant Depression. <i>Journal of ECT</i> , 2009, 25, 178-181.	0.6	3
287	Predictors of Clinical Worsening After a Switch to Aripiprazole in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 394-395.	1.4	18
288	D ₂ Receptor Blockade by Risperidone Correlates With Attention Deficits in Late-Life Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 571-575.	1.4	41

#	ARTICLE	IF	CITATIONS
289	Increased Antipsychotic Sensitivity in Elderly Patients. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 397-405.	2.2	104
290	Selective Serotonin Reuptake Inhibitorâ€“Induced Spermatorrhea in 2 Patients. <i>Journal of Clinical Psychiatry</i> , 2009, 70, 1192-1193.	2.2	5
291	Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an openâ€“label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. <i>Human Psychopharmacology</i> , 2008, 23, 455-463.	1.5	43
292	Novel rating scales for schizophrenia â€” Targeted Inventory on Problems in Schizophrenia (TIP-Sz) and Functional Assessment for Comprehensive Treatment of Schizophrenia (FACT-Sz). <i>Schizophrenia Research</i> , 2008, 106, 328-336.	2.0	27
293	Effects of Age and Age of Onset on Prescribed Antipsychotic Dose in Schizophrenia Spectrum Disorders: A Survey of 1,418 Patients in Japan. <i>American Journal of Geriatric Psychiatry</i> , 2008, 16, 584-593.	1.2	45
294	A Randomized, Open-Label Comparison of 2 Switching Strategies to Aripiprazole Treatment in Patients With Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 540-543.	1.4	32
295	Quetiapine Extended-Release Versus Immediate-Release Formulation. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 81-86.	2.2	40
296	Monthly Administration of Long-Acting Injectable Risperidone and Striatal Dopamine D2 Receptor Occupancy for the Management of Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2008, 69, 1281-1286.	2.2	46
297	A potentially aborted neuroleptic malignant syndrome following seclusion against uncontrollable water intoxication. <i>Psychopharmacology Bulletin</i> , 2008, 41, 164-70.	0.0	3
298	Treatment target in schizophrenia: a critical review and a clinical suggestion. <i>Psychopharmacology Bulletin</i> , 2008, 41, 80-102.	0.0	11
299	An Open-Label Trial of Discontinuing Benzodiazepines in Patients With Chronic Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 401-403.	1.4	6
300	Reply to Comments by Dr Magalhães. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 318-319.	1.4	0
301	Treating a schizophrenic patient with severe tardive dystonia without antipsychotics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007, 31, 1141-1142.	4.8	3
302	Dietary nitrite inhibits early glomerular injury in streptozotocin-induced diabetic nephropathy in rats. <i>Nitric Oxide - Biology and Chemistry</i> , 2007, 17, 75-81.	2.7	30
303	Minimizing antipsychotic medication obviated the need for enema against severe constipation leading to paralytic ileus: a case report. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2007, 32, 525-527.	1.5	13
304	How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?â€“A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. <i>Psychopharmacology</i> , 2007, 195, 285-295.	3.1	49
305	Antipsychotics-induced hypersensitivity of visual perception. <i>European Psychiatry</i> , 2006, 21, 343-344.	0.2	9
306	Reducing the Dose of Antipsychotic Agents Ameliorates Visual Hypersensitivity Attack. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 50-55.	1.4	13

#	ARTICLE	IF	CITATIONS
307	Combined Treatment With Sulpiride and Paroxetine for Accelerated Response in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 545-551.	1.4	20
308	A randomized open-label trial of paroxetine versus paroxetine plus sulpiride in the treatment of major depressive disorder. <i>International Clinical Psychopharmacology</i> , 2005, 20, A16.	1.7	0
309	Simplifying psychotropic medication regimen into a single night dosage and reducing the dose for patients with chronic schizophrenia. <i>Psychopharmacology</i> , 2005, 181, 566-575.	3.1	20
310	Two Case Reports of Successful Prevention of Overdosing in Borderline Patients. <i>Psychiatry (New Tj ETQq0 0 0 rgBTJ/Overlock 10 Tf 50</i>	0.7	4
311	A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2004, 28, 361-369.	4.8	28
312	Simplifying psychotropic medication regimen into a single night dosing and reducing the dose for patients with chronic, stable schizophrenia. <i>International Clinical Psychopharmacology</i> , 2004, 19, 183.	1.7	0
313	Revising polypharmacy to a single antipsychotic regimen for patients with chronic schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2004, 7, 133-142.	2.1	90
314	Dose reduction of antipsychotic agents ameliorates paroxysmal perceptual alteration: a controlled study. <i>International Clinical Psychopharmacology</i> , 2004, 19, 180-181.	1.7	0
315	Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. <i>International Clinical Psychopharmacology</i> , 2003, 18, 323-329.	1.7	30
316	Recurrent Episodes of Perceptual Alteration in Patients Treated With Antipsychotic Agents. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 496-499.	1.4	22
317	Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia. <i>International Clinical Psychopharmacology</i> , 2003, 18, 323-329.	1.7	15
318	Antipsychotic-Induced Paroxysmal Perceptual Alteration. <i>American Journal of Psychiatry</i> , 2003, 160, 2243-a-2244.	7.2	16
319	Fluctuating PEEP versus conventional PEEP in diffuse and unilateral lung injury induced by oleic acid. <i>Acta Anaesthesiologica Scandinavica</i> , 1988, 32, 420-425.	1.6	8
320	Characteristic findings of perianal lesions in Japanese patients with Crohn's disease.. <i>Nihon Daicho Komonbyo Gakkai Zasshi</i> , 1987, 40, 369-379.	0.0	0
321	Electrical stimulation of the gastrointestinal muscle and nerve in surgery of the gastrointestinal tract. <i>Gastroenterologia Japonica</i> , 1968, 3, 427-427.	0.3	0